JP2018502051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502051A5 JP2018502051A5 JP2017518540A JP2017518540A JP2018502051A5 JP 2018502051 A5 JP2018502051 A5 JP 2018502051A5 JP 2017518540 A JP2017518540 A JP 2017518540A JP 2017518540 A JP2017518540 A JP 2017518540A JP 2018502051 A5 JP2018502051 A5 JP 2018502051A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cancer
- polypeptide
- seq
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062323P | 2014-10-10 | 2014-10-10 | |
| US62/062,323 | 2014-10-10 | ||
| US201562118549P | 2015-02-20 | 2015-02-20 | |
| US62/118,549 | 2015-02-20 | ||
| US201562133597P | 2015-03-16 | 2015-03-16 | |
| US62/133,597 | 2015-03-16 | ||
| US201562188881P | 2015-07-06 | 2015-07-06 | |
| US62/188,881 | 2015-07-06 | ||
| PCT/EP2015/073370 WO2016055609A1 (en) | 2014-10-10 | 2015-10-09 | Cd73 blockade |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020122032A Division JP7132981B2 (ja) | 2014-10-10 | 2020-07-16 | Ｃｄ７３遮断 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502051A JP2018502051A (ja) | 2018-01-25 |
| JP2018502051A5 true JP2018502051A5 (https=) | 2018-11-22 |
| JP7037359B2 JP7037359B2 (ja) | 2022-03-16 |
Family
ID=54291300
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017518540A Active JP7037359B2 (ja) | 2014-10-10 | 2015-10-09 | Ｃｄ７３遮断 |
| JP2020122032A Active JP7132981B2 (ja) | 2014-10-10 | 2020-07-16 | Ｃｄ７３遮断 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020122032A Active JP7132981B2 (ja) | 2014-10-10 | 2020-07-16 | Ｃｄ７３遮断 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10766966B2 (https=) |
| EP (2) | EP3736294A3 (https=) |
| JP (2) | JP7037359B2 (https=) |
| KR (1) | KR102536786B1 (https=) |
| CN (1) | CN106852149B (https=) |
| AU (2) | AU2015329982B2 (https=) |
| CA (1) | CA2957813C (https=) |
| DK (1) | DK3204417T3 (https=) |
| ES (1) | ES2821964T3 (https=) |
| IL (1) | IL250579B2 (https=) |
| MX (1) | MX384346B (https=) |
| PT (1) | PT3204417T (https=) |
| RU (1) | RU2746804C2 (https=) |
| SG (1) | SG11201701341UA (https=) |
| WO (1) | WO2016055609A1 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL250579B2 (en) * | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| WO2016131950A1 (en) * | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| DK3218406T4 (da) | 2014-11-10 | 2024-12-09 | Medimmune Ltd | Bindingsmolekyler, der er specifikke for cd73, og anvendelser deraf |
| MY189836A (en) | 2014-11-21 | 2022-03-11 | Bristol Myers Squibb Co | Antibodies against cd73 and uses thereof |
| JP6668345B2 (ja) | 2014-11-21 | 2020-03-18 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 修飾された重鎖定常領域を含む抗体 |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| WO2017118613A1 (en) * | 2016-01-08 | 2017-07-13 | Syddansk Universitet | Bispecific antibodies targeting human cd73 |
| KR20230038311A (ko) * | 2016-03-04 | 2023-03-17 | 브리스톨-마이어스 스큅 컴퍼니 | 항-cd73 항체와의 조합 요법 |
| KR102379464B1 (ko) | 2016-06-20 | 2022-03-29 | 키맵 리미티드 | 항-pd-l1 항체 |
| WO2018013611A1 (en) * | 2016-07-11 | 2018-01-18 | Corvus Pharmaceuticals, Inc. | Anti-cd73 antibodies |
| US11180554B2 (en) | 2016-12-13 | 2021-11-23 | Astellas Pharma Inc. | Anti-human CD73 antibody |
| EP3383916B1 (en) * | 2017-01-24 | 2022-02-23 | I-Mab Biopharma US Limited | Anti-cd73 antibodies and uses thereof |
| CN110382544B (zh) | 2017-03-16 | 2023-12-22 | 先天制药公司 | 用于治疗癌症的组合物和方法 |
| WO2018187512A1 (en) * | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods for treating cd73hi tumors |
| WO2018215535A1 (en) * | 2017-05-23 | 2018-11-29 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Novel cd73 antibody, preparation and uses thereof |
| CN118307674A (zh) * | 2017-06-22 | 2024-07-09 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| WO2018237173A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019068907A1 (en) | 2017-10-06 | 2019-04-11 | Innate Pharma | RESTORATION OF T CELL ACTIVITY BY AXIS CD39 / CD73 |
| SG11202002195YA (en) * | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
| BR112020010579A2 (pt) | 2017-11-30 | 2020-11-10 | Novartis Ag | receptor de antígeno quimérico de alvejamento de bcma e usos do mesmo |
| BR122023024273A2 (pt) | 2018-02-27 | 2024-02-20 | Incyte Corporation | Compostos imidazopirimidinas e triazolopirimidinas, seus usos, método para inibir uma atividade de um receptor de adenosina e composição farmacêutica dos mesmos |
| KR102804816B1 (ko) * | 2018-03-09 | 2025-05-09 | 페인스 테라퓨틱스 인코포레이티드 | 항-cd73 항체 및 이의 용도 |
| TWI823906B (zh) | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
| US20210147570A1 (en) | 2018-04-12 | 2021-05-20 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
| WO2019222677A1 (en) | 2018-05-18 | 2019-11-21 | Incyte Corporation | Fused pyrimidine derivatives as a2a / a2b inhibitors |
| EP3569618A1 (en) | 2018-05-19 | 2019-11-20 | Boehringer Ingelheim International GmbH | Antagonizing cd73 antibody |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| UY38251A (es) | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| MX2020012107A (es) | 2018-06-18 | 2021-01-29 | Innate Pharma | Composiciones y procedimientos para el tratamiento del cancer. |
| GEP20237548B (en) | 2018-07-05 | 2023-10-10 | Incyte Corp | Fused pyrazine derivatives as a2a /a2b inhibitors |
| WO2020020307A1 (en) | 2018-07-25 | 2020-01-30 | I-Mab Biopharma Co., Ltd. | Anti-cd73 anti-pd-l1 bispecific antibodies |
| US20200345725A1 (en) | 2019-01-11 | 2020-11-05 | Omeros Corporation | Methods and Compositions for Treating Cancer |
| CN111499747B (zh) * | 2019-01-11 | 2022-03-18 | 康诺亚生物医药科技（成都）有限公司 | 一种抗cd73单克隆抗体及其应用 |
| TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶 |
| SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
| EA202193351A1 (ru) * | 2019-06-06 | 2022-03-21 | Джакобио Фармасьютикалс Ко., Лтд. | Связывающая молекула, специфическая в отношении cd73, и применение связывающей молекулы |
| CN112300279A (zh) * | 2019-07-26 | 2021-02-02 | 上海复宏汉霖生物技术股份有限公司 | 针对抗cd73抗体和变体的方法和组合物 |
| US20230357425A1 (en) * | 2019-08-21 | 2023-11-09 | Harbour Biomed (Shanghai) Co., Ltd | Anti-cd73 antibody and application thereof |
| US11634500B2 (en) | 2019-09-06 | 2023-04-25 | Les Laboratoires Servier | Anti-CD73 antibodies and compositions |
| US20220348651A1 (en) | 2019-09-18 | 2022-11-03 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| EP4058150A2 (en) * | 2019-11-15 | 2022-09-21 | Genzyme Corporation | Biparatopic cd73 antibodies |
| JP7772700B2 (ja) * | 2019-12-19 | 2025-11-18 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 神経膠芽腫を処置するための方法 |
| WO2021138467A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Anti-cd73 antibodies and uses thereof |
| CA3166536A1 (en) | 2020-01-03 | 2021-07-08 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
| BR112022021397A2 (pt) * | 2020-04-22 | 2023-02-07 | Akeso Biopharma Inc | Anticorpo anti-cd73, polipeptídeo isolado, molécula de ácido nucleico, vetor, célula hospedeira, conjugado, proteína de fusão ou anticorpo multiespecífico, kit, composição farmacêutica, uso do anticorpo e linhagem celular de hibridoma |
| WO2021247188A1 (en) | 2020-06-05 | 2021-12-09 | Bristol-Myers Squibb Company | Cd73 antagonist potency assay and methods of use thereof |
| CN115734972A (zh) * | 2020-06-22 | 2023-03-03 | 信达生物制药(苏州)有限公司 | 抗cd73抗体及其用途 |
| EP4178615A4 (en) * | 2020-07-10 | 2024-07-24 | Biomolecular Holdings LLC | TETRAHEDRAL ANTIBODIES |
| WO2022033978A2 (en) | 2020-08-13 | 2022-02-17 | Innate Pharma | Cancer treatment methods using anti-cd73 antibodies |
| EP4197555A4 (en) * | 2020-08-17 | 2025-03-12 | Akeso Biopharma, Inc. | ANTI-CD73 ANTIBODIES AND USE THEREOF |
| US20240018254A1 (en) * | 2020-10-23 | 2024-01-18 | Akeso Biopharma, Inc | Anti-cd73 antibody and use thereof |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| TWI900705B (zh) * | 2020-12-11 | 2025-10-11 | 大陸商上海華奧泰生物藥業股份有限公司 | Ｃｄ７３的抗原結合蛋白及其應用 |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| MX2023007850A (es) | 2020-12-29 | 2023-09-11 | Incyte Corp | Terapia combinada que comprende inhibidores de adora2a/adora2b (a2a/a2b), inhibidores de muerte programada/ligando 1 de muerte programada (pd-1/pd-l1) y anticuerpos de cumulo de diferenciacion 73 (anti-cd73). |
| WO2022235569A1 (en) * | 2021-05-05 | 2022-11-10 | Corvus Pharmaceuticals, Inc. | Anti-cd73 compounds to treat oncovirus-positive cancers |
| US12187806B2 (en) | 2022-03-04 | 2025-01-07 | Development Center For Biotechnology | Anti-CD73 antibodies and use thereof |
| CN119173276A (zh) | 2022-04-13 | 2024-12-20 | 吉利德科学公司 | 用于治疗表达Trop-2的癌症的组合疗法 |
| WO2023206242A1 (zh) * | 2022-04-28 | 2023-11-02 | 江苏中新医药有限公司 | 无钩状效应的抗人cd73单克隆抗体 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| WO2025162964A1 (en) | 2024-01-30 | 2025-08-07 | Institut National de la Santé et de la Recherche Médicale | Methods for the treatment of endometriosis |
| WO2025233264A1 (en) | 2024-05-07 | 2025-11-13 | Innate Pharma | Use of cd73 blocking agents in combination with anti-cd20 x cd3 t cell engagers |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
| JP4462964B2 (ja) * | 2003-03-10 | 2010-05-12 | 第一三共株式会社 | 癌特異的抗原を標的とした抗体 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| EP2975057A1 (en) | 2006-07-10 | 2016-01-20 | Fujita Health University | Novel anti-cd73 antibody |
| US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
| US20090130092A1 (en) * | 2007-10-30 | 2009-05-21 | Pinsky David J | Nucleotide phosphate dissipation as a treatment for vascular disorders |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| NZ628923A (en) | 2009-11-24 | 2016-02-26 | Medimmune Ltd | Targeted binding agents against b7-h1 |
| ES2751549T3 (es) | 2009-11-30 | 2020-04-01 | Janssen Biotech Inc | Mutantes de anticuerpos Fc con funciones efectoras ablacionadas |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| CA2822366A1 (en) | 2010-12-23 | 2012-06-28 | Janssen Biotech, Inc. | Active protease-resistant antibody fc mutants |
| KR101970025B1 (ko) | 2011-04-20 | 2019-04-17 | 메디뮨 엘엘씨 | Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들 |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| WO2013165690A1 (en) | 2012-04-30 | 2013-11-07 | Medimmune, Llc | Molecules with reduced effector function and extended half-lives, compositions, and uses thereof |
| US9090697B2 (en) * | 2013-03-15 | 2015-07-28 | Bayer Healthcare Llc | Methods for treating bleeding disorders |
| CN103278634B (zh) * | 2013-05-16 | 2015-01-07 | 中国科学院近代物理研究所 | Cd73作为肾透明细胞癌干细胞表面标志物的应用 |
| MY184154A (en) | 2013-12-12 | 2021-03-23 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2016131950A1 (en) | 2015-02-20 | 2016-08-25 | Innate Pharma | Cd73 blockade |
| IL250579B2 (en) | 2014-10-10 | 2023-05-01 | Innate Pharma | blocking cd73 |
| US20180030144A1 (en) | 2014-10-10 | 2018-02-01 | Innate Pharma | Cd73 blockade |
| AU2016299166B2 (en) | 2015-07-24 | 2022-03-31 | Innate Pharma | Methods for detecting tissue infiltrating NK cells |
| US11130817B2 (en) | 2015-10-12 | 2021-09-28 | Innate Pharma | CD73 blocking agents |
| US20190071514A1 (en) | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
| US20200023071A1 (en) | 2017-02-06 | 2020-01-23 | Innate Pharma | Immunomodulatory antibody drug conjugates binding to a human mica polypeptide |
| SG11202111106WA (en) | 2019-04-23 | 2021-11-29 | Innate Pharma | Cd73 blocking antibodies |
-
2015
- 2015-10-09 IL IL250579A patent/IL250579B2/en unknown
- 2015-10-09 KR KR1020177011231A patent/KR102536786B1/ko active Active
- 2015-10-09 RU RU2017105119A patent/RU2746804C2/ru active
- 2015-10-09 CN CN201580055012.7A patent/CN106852149B/zh active Active
- 2015-10-09 EP EP20180074.5A patent/EP3736294A3/en active Pending
- 2015-10-09 CA CA2957813A patent/CA2957813C/en active Active
- 2015-10-09 DK DK15778310.1T patent/DK3204417T3/da active
- 2015-10-09 SG SG11201701341UA patent/SG11201701341UA/en unknown
- 2015-10-09 PT PT157783101T patent/PT3204417T/pt unknown
- 2015-10-09 US US15/517,991 patent/US10766966B2/en active Active
- 2015-10-09 AU AU2015329982A patent/AU2015329982B2/en active Active
- 2015-10-09 MX MX2017004691A patent/MX384346B/es unknown
- 2015-10-09 EP EP15778310.1A patent/EP3204417B1/en active Active
- 2015-10-09 ES ES15778310T patent/ES2821964T3/es active Active
- 2015-10-09 WO PCT/EP2015/073370 patent/WO2016055609A1/en not_active Ceased
- 2015-10-09 JP JP2017518540A patent/JP7037359B2/ja active Active
-
2020
- 2020-07-16 JP JP2020122032A patent/JP7132981B2/ja active Active
- 2020-09-02 US US17/009,817 patent/US11958907B2/en active Active
-
2021
- 2021-08-16 AU AU2021215306A patent/AU2021215306A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502051A5 (https=) | ||
| CN112714768B (zh) | 新型抗cd39抗体 | |
| TWI526223B (zh) | 人化ａｘｌ抗體類 | |
| CN111542539B (zh) | 通过cd39/cd73轴恢复t细胞活性 | |
| CN106659779B (zh) | 双特异性四价抗体及其制造和使用方法 | |
| AU2015316991B2 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| JP2024009935A (ja) | 抗体、活性化可能抗体、二重特異性抗体、および二重特異性活性化可能抗体ならびにその使用方法 | |
| KR102795728B1 (ko) | 암 치료를 위해 t 세포 활성화제 및/또는 펩티드 억제제와 조합된 펩티드 및 펩티드모방체 | |
| WO2023020621A1 (en) | Anti-ccr8 antibodies and uses thereof | |
| RU2017105119A (ru) | Блокада cd73 | |
| AU2024202552A1 (en) | Neutralization of inhibitory pathways in lymphocytes | |
| JP2020536109A5 (https=) | ||
| RU2012137515A (ru) | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения | |
| JP2018503365A5 (https=) | ||
| RU2012126138A (ru) | Специфические связывающие агенты против в7-н1 | |
| JP2015525208A5 (https=) | ||
| WO2014012007A4 (en) | Rspo3 binding agents and uses thereof | |
| JP2020524675A (ja) | Ｃｄ３８抗体薬物コンジュゲート | |
| CA2786479A1 (en) | Methods for treating pancreatic cancer | |
| AR070821A1 (es) | Anticuerpo anti- tyrp1 (antitiroxina humana) | |
| EP2046836A4 (en) | SPECIALLY ANTIBODY BONDING DR5 AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER CONTAINING THEREOF | |
| JP2018512124A5 (https=) | ||
| CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
| JP2014515600A5 (https=) | ||
| JP2021521274A5 (https=) |